Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eiger Biopharma (EIGR)

Eiger Biopharma (EIGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 259,372
  • Shares Outstanding, K 24,446
  • Annual Sales, $ 0 K
  • Annual Income, $ -52,390 K
  • 60-Month Beta 1.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.77
  • Number of Estimates 3
  • High Estimate -0.72
  • Low Estimate -0.82
  • Prior Year -1.20
  • Growth Rate Est. (year over year) +35.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.51 +15.66%
on 10/02/19
12.05 -8.71%
on 09/17/19
-0.93 (-7.80%)
since 09/16/19
3-Month
9.51 +15.66%
on 10/02/19
12.50 -11.99%
on 09/11/19
-0.16 (-1.43%)
since 07/16/19
52-Week
8.40 +30.95%
on 11/20/18
15.33 -28.25%
on 04/03/19
+0.13 (+1.20%)
since 10/16/18

Most Recent Stories

More News
Eiger to Present at Cantor 2019 Global Healthcare Conference

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will...

EIGR : 11.00 (+3.68%)
Eiger BioPharmaceuticals to Participate in September Conferences

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate...

EIGR : 11.00 (+3.68%)
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration...

EIGR : 11.00 (+3.68%)
Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the...

EIGR : 11.00 (+3.68%)
Eiger BioPharmaceuticals to Participate in Investor Conferences in August

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate...

EIGR : 11.00 (+3.68%)
What Makes Eiger BioPharma (EIGR) a New Buy Stock

Eiger BioPharma (EIGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EIGR : 11.00 (+3.68%)
Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach, PhD, RPh...

EIGR : 11.00 (+3.68%)
Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd,...

EIGR : 11.00 (+3.68%)
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2, multi-center...

EIGR : 11.00 (+3.68%)
Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step...

EIGR : 11.00 (+3.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade EIGR with:

Business Summary

Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.

See More

Key Turning Points

2nd Resistance Point 11.34
1st Resistance Point 11.17
Last Price 11.00
1st Support Level 10.69
2nd Support Level 10.38

See More

52-Week High 15.33
Fibonacci 61.8% 12.68
Fibonacci 50% 11.86
Fibonacci 38.2% 11.05
Last Price 11.00
52-Week Low 8.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar